Arzoxifene hydrochloride is a selective estrogen receptor modulator that is a potent estrogen antagonist in mammary and uterine tissue.

4-Hydroxytamoxifen (ICI 79280) is the active metabolite of Tamoxifen, an estrogen receptor modulator (SERM) with selective and oral potency. 4-Hydroxytamoxifen has antitumor activity and may be used in breast cancer research.

Chlorotrianisene (tri-p-anisylchloroethylene) is an orally bioavailable, highly lipophilic, synthetic triphenylethylene (TPE) derivative and selective estrogen receptor modulator (SERM), with predominantly estrogenic but also antiestrogenic activities.

Disermolide is a polyketide natural product found to stabilize microtubules. Disermolide was found to be a potent inhibitor of tumor cell growth in several MDR cancer cell lines.

Indazole-Cl is a selective ERß agonist and a selective estrogen receptor modifier (SERM).

Fispemifene (HM-101) is an estrogen receptor modulator (SERM) used to treat genitourinary syndromes and vaginal atrophy.

Sermetacin is an anti-inflammatory agent.

Mecasermin (Human IGF-I; FK 780), a recombinant form of human insulin-like growth factor I (IGF-I), holds promise for investigating growth failure attributed to growth hormone (GH) insensitivity, which may be due to defects in GH receptors or the presence of GH-inhibiting antibodies [1].

Raloxifene hydrochloride (LY156758 hydrochloride) is a second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Bazedoxifene hydrochloride (TSE-424) is a novel, non-steroidal, indole-based estrogen receptor modulator (SERM) binding to both ERα and ERβ with IC50 of 23 nM and 89 nM, respectively.

Bazedoxifene acetate (WAY-TES 424) is a novel selective estrogen receptor modulator (SERM).

Raloxifene (LY-139481) is a selective oestrogen receptor modulator. It has effects on bone and breast cancer and cardiovascular disease risk.

Tamoxifen-d5 is a deuterium labeled Tamoxifen. Tamoxifen is a selective modulator of estrogen receptor (SERM). Tamoxifen is a potent activator of Hsp90 and enhances the Hsp90 molecular chaperone ATPase activity.

ER degrader 6 (compound 35s) is a potent selective estrogen receptor modulator (SERM) with the capacity to degrade Estrogen Receptor (ER)α. It disrupts the microtubule network, inhibiting tubulin polymerization, and effectively suppresses tumor growth with minimal toxicity [1].

TFR4OHT is a selective ER modulator (SERM).

Lasofoxifene (CP-336156) is a selective, orally active estrogen receptor modulator (SERM) that inhibits the growth and metastasis of primary tumours and is also anti-osteoporotic.

Endoxifen E-isomer hydrochloride (E-Endoxifen hydrochloride) , a tamoxifen metabolite, is effective specific Estrogen Response Modifier (SERM).

LY-329146 is a selective estrogen receptor modulator (SERM). LY-329146 prevents doxorubicin resistance in tumor cells expressing multidrug resistance-associated protein (MRP) by inhibiting the binding of MRP substrates to the estrogen receptor.

Levormeloxifene fumarate is an osteoporosis drug and selective estrogen receptor modulator (SERM).

Estrogen receptor modulator 1 causes regression of Tamoxifen-resistant, hormone-independent xenograft tumors. Estrogen receptor modulator 1 is an orally active and selective estrogen receptor modulator (SERM) (pIC50: 0.46).

Clomifene is a selective estrogen receptor modulator (SERM), it has both estrogenic and anti-estrogenic activities. This agent causes the release of the pituitary gonadotropins follicle-stimulating hormone (FSH) and luteinizing hormone (LH), leading to ov

Toremifene (GTx 006) is a selective estrogen-receptor modulator (SERM).

Arzoxifene (LY353381) is an orally active selective estrogen receptor modulator (SERM) exhibiting a fixed ring structure analogous to raloxifene. This compound demonstrates potent antiestrogenic effects on breast cancer and endometrium while displaying minimal side effects. Additionally, Arzoxifene elicits favorable estrogenic effects on bone health and lipid profile.

Lasofoxifene Tartrate (CP-336156) is a third-generation, non-steroidal selective estrogen receptor modulator.

Endoxifen, also known as N-desmethyl-4-hydroxytamoxifen, is a chemical that is under development for estrogen receptor-positive breast cancer. It is also being evaluated as an antipsychotic for treatment of mania and other psychotic disorders. Endoxifen is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group. It is an active metabolite of tamoxifen and has been found to be effective in patients that have failed previous hormonal therapies (tamoxifen, aromatase inhibitors, and fulvestrant). The prodrug tamoxifen is metabolized by the CYP2D6 enzyme to produce afimoxifene (4-hydroxytamoxifen) and endoxifen.

Tamoxifen is an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM).